Literature DB >> 32830346

Pathogenic germline variants in patients with features of hereditary renal cell carcinoma: Evidence for further locus heterogeneity.

Philip S Smith1, Hannah West1, James Whitworth1, Bruce Castle2, Francis H Sansbury2,3, Anne Y Warren4, Emma R Woodward5, Marc Tischkowitz1, Eamonn R Maher1.   

Abstract

Inherited renal cell carcinoma (RCC) is associated with multiple familial cancer syndromes but most individuals with features of non-syndromic inherited RCC do not harbor variants in the most commonly tested renal cancer predisposition genes (CPGs). We investigated whether undiagnosed cases might harbor mutations in CPGs that are not routinely tested for by testing 118 individuals with features suggestive of inherited RCC (family history of RCC, two or more primary RCC aged <60 years, or early onset RCC ≤46 years) for the presence of pathogenic variants in a large panel of CPGs. All individuals had been prescreened for pathogenic variants in the major RCC genes. We detected pathogenic or likely pathogenic (P/LP) variants of potential clinical relevance in 16.1% (19/118) of individuals, including P/LP variants in BRIP1 (n = 4), CHEK2 (n = 3), MITF (n = 1), and BRCA1 (n = 1). Though the power to detect rare variants was limited by sample size the frequency of truncating variants in BRIP1, 4/118, was significantly higher than in controls (P = 5.92E-03). These findings suggest that the application of genetic testing for larger inherited cancer gene panels in patients with indicators of a potential inherited RCC can increase the diagnostic yield for P/LP variants. However, the clinical utility of such a diagnostic strategy requires validation and further evaluation and in particular, confirmation of rarer RCC genotype-phenotype associations is required.
© 2020 The Authors. Genes, Chromosomes and Cancer published by Wiley Periodicals LLC.

Entities:  

Keywords:  inherited; predisposition; renal cell carcinoma

Year:  2020        PMID: 32830346     DOI: 10.1002/gcc.22893

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  5 in total

1.  Down-regulation of BCL2L13 renders poor prognosis in clear cell and papillary renal cell carcinoma.

Authors:  Fei Meng; Luojin Zhang; Mingjun Zhang; Kaiqin Ye; Wei Guo; Yu Liu; Wulin Yang; Zhimin Zhai; Hongzhi Wang; Jun Xiao; Haiming Dai
Journal:  Cancer Cell Int       Date:  2021-06-30       Impact factor: 5.722

Review 2.  CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate.

Authors:  Lenka Stolarova; Petra Kleiblova; Marketa Janatova; Jana Soukupova; Petra Zemankova; Libor Macurek; Zdenek Kleibl
Journal:  Cells       Date:  2020-12-12       Impact factor: 6.600

3.  Germline Mutation Landscape and Associated Clinical Characteristics in Chinese Patients With Renal Cell Carcinoma.

Authors:  Wen Kong; Tongtong Yang; Xiaodong Wen; Zhongyi Mu; Cheng Zhao; Sujun Han; Jing Tian; Xinhao Zhang; Tao Zhou; Yanrui Zhang; Feng Lou; Shanbo Cao; Huina Wang; Jin Zhang
Journal:  Front Oncol       Date:  2021-12-02       Impact factor: 6.244

4.  Frequency of pathogenic germline variants in cancer susceptibility genes in 1336 renal cell carcinoma cases.

Authors:  Bryndis Yngvadottir; Avgi Andreou; Laia Bassaganyas; Alexey Larionov; Alex J Cornish; Daniel Chubb; Charlie N Saunders; Philip S Smith; Huairen Zhang; Yasemin Cole; Genomics England Research Consortium; James Larkin; Lisa Browning; Samra Turajlic; Kevin Litchfield; Richard S Houlston; Eamonn R Maher
Journal:  Hum Mol Genet       Date:  2022-08-25       Impact factor: 5.121

5.  The PI3K/mTOR Pathway Is Targeted by Rare Germline Variants in Patients with Both Melanoma and Renal Cell Carcinoma.

Authors:  Jean-Noël Hubert; Voreak Suybeng; Maxime Vallée; Tiffany M Delhomme; Eve Maubec; Anne Boland; Delphine Bacq; Jean-François Deleuze; Fanélie Jouenne; Paul Brennan; James D McKay; Marie-Françoise Avril; Brigitte Bressac-de Paillerets; Estelle Chanudet
Journal:  Cancers (Basel)       Date:  2021-05-07       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.